Table 1.
Comparisons of vascular endothelial growth factor (VEGF), CXCL16, CX3CL1, ADAM10 and ADAM17 levels in proliferative diabetic retinopathy (PDR) patients with or without active neovascularization and nondiabetic patients with rhegmatogenous retinal detachment (RD).
| Disease group | VEGF (pg/ml) | CXCL16 (pg/ml) | CX3CL1 (pg/ml) | ADAM10 (pg/ml) | ADAM17 (pg/ml) |
|---|---|---|---|---|---|
| • RD (n=24) Median [IQR] |
11.0 (0.0–46.8) |
2156.3 (1456.3–2903.1) |
4.7 (1.3–7.4) |
1215.0 (1108.3–1409.2 |
315.6 190.8–343.6) |
| • All PDR (n=32) Median [IQR] |
185.5 (92.3–1484.5) |
9306.3 (6543.8–9881.3) |
22.3 (15.3–25.0) |
1870.0 (1569.2–2217.5) |
486.1 (226.9–1365.8) |
| p-value (Mann-Whitney test) |
<0.001* | <0.001* | <0.001* | <0.001* | 0.005* |
| • Active PDR (n=16) Median [IQR] |
1424.5 (103.3–1657.5) |
9593.8 (9321.9–9890.6) |
23.7 (21.8–38.2) |
2128.3 (1817.5–2585.0) |
1433.3 (1092.5–1783.9) |
| • Inactive PDR (n=16) Median [IQR] |
108.0 (77.3–365.8) |
6543.8 (5281.3–9706.3) |
16.3 (11.6–23.7) |
1671.7 (1335.0–2050.0) |
237.8 (215.6–429.2) |
| • RD (n=24) Median [IQR] |
11.0 (0.0–46.8) |
2156.3 (1456.3–2903.1) |
4.7 (1.3–7.4) |
1215.0 (1108.3–1409.2 |
315.6 190.8–343.6) |
| p-value (Kruskal-Wallis test) |
<0.001* | <0.001* | <0.001* | <0.001* | <0.001* |
*Statistically significant at 5% level of significance.
IQR, interquartile range.